White & Case Advises Famy Life Sciences on Its Acquisition by Viatris Inc.
1 min read
Global law firm White & Case LLP has advised Famy Life Sciences, a market-leading drug development platform, on its entry into a definitive agreement to be acquired by Viatris Inc., a global healthcare company, which is also acquiring Oyster Point Pharma, for an aggregate value of approximately US$700-$750 million.
Upon closing, Viatris intends to create a leading global ophthalmology franchise with the combination of Viatris' global commercial footprint, Oyster Point’s ophthalmology knowledge, and Famy Life Sciences' Phase III-ready pipeline. The franchise, which will operate as a separate division within the company, will accelerate Viatris’ efforts to address the unmet needs of patients with ophthalmic disease and the eye care professionals who treat them, and is expected to bring in approximately US$1 billion in sales by 2028.
Famy Life Sciences is a drug development platform focused on innovation in medicine and healthcare. The company identifies and develops best-in-class clinical-stage assets in different therapeutics areas such as ophthalmology, oncology, dermatology and others, to bring to market.
The White & Case team was led by M&A partner James Hu, Technology & Transactions partner Andres Liivak, Project Development and Finance partner Nandan Nelivigi and Tax partner Scott Fryman (all in New York), and included M&A associate Matthew Anderson (New York) and Technology Transactions associate Ajita Shukla (Washington, DC). Law clerk Dilara Erik assisted on the matter.
For more information please speak to your local media contact.